Hyperway
Latest round
- Series B
Last raised
- Oct 2025
Total raised
- $14M
Investors
- 13
About Hyperway
Established in 2019 and based in Chengdu, China, Hyperway is a biopharmaceutical company that focuses on the research and development of innovative and generic drugs. The company has won the 2021 Chengdu New Economy Hundred Key Cultivation Enterprises, Chengdu New Economy Double Hundred Enterprises, and so on. As of 2024, the team has more than 100 employees, with R&D personnel accounting for over 80%. The founder and chairman of the board, Yingfu Li has nearly 30 years of experience in drug discovery and management and served as Deputy General Manager, General Manager, and Group Vice President of ChemPartner. Hyperway is committed to the research and development of innovative drugs. It has built a technology platform for the development and evaluation of brain-penetrating drugs, including molecular design, molecular synthesis and screening, pharmacokinetic evaluation, and toxicology research. The innovative drug research and development pipeline covers multiple treatment fields such as tumor resistance, tumor immunity, central nervous system, etc. The innovative products include HBW-3220, HBW-004285, and HBW-012. The company generates revenue by providing innovative drugs. The company will use the funds for the clinical studies of three innovative drugs, HBW-3220, HBW-3210, and HBW-004285, as well as the advancement of multiple preclinical innovative drug development pipelines.
Who invested in Hyperway
13 investors across 5 rounds
See all investors in Hyperway
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hyperway
Who invested in Hyperway?
Hyperway has 13 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hyperway raised?
Hyperway has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Hyperway last raise money?
Hyperway's most recent round on record is a Series B, in Oct 2025.
What does Hyperway do?
Established in 2019 and based in Chengdu, China, Hyperway is a biopharmaceutical company that focuses on the research and development of innovative and generic drugs.
Where is Hyperway headquartered?
Hyperway is headquartered in Chengdu, China.
Which VCs invest in companies like Hyperway?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Hyperway's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Hyperway? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.